The development of platforms for the controlled release of therapeutic molecules remains a crucial research focus, as controlled release reduces the frequency of administration, minimizes side effects and improves compliance. However, biological conditions and diseases with a progression that exhibits strong temporal dependence, or those that can result in the evolution of tolerance to the therapeutic during continuous exposure, require the development of sophisticated release systems tailored to the needs to the individual and the disease. Thus, there has been emphasis on the development of platforms with remotely controlled release mechanisms. Specifically, magnetically triggered release utilizes magnetic nanoparticles as the remote control modality. Many reviews discuss the magnetically triggered release of small molecule drugs, however, the release of biomacromolecules has not been reviewed. This review examines the limited work on the magnetically triggered release of biomacromolecules and the challenges associated with their delivery. Important material parameters that have been used in this pursuit are discussed.
Get full access to this article
View all access options for this article.
References
1.
ParkK.Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3–8. doi: 10.1016/j.jconrel.2014.03.054
2.
UllyotGEUllyotBHSlaterLB.The metamorphosis of Smith-Kline & French laboratories to Smith Kline. Bull Hist Chem. 2000;25(1):16–20.
LangerRSPeppasNA.Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials. 1981;2(4):201–214. doi: 10.1016/0142-9612(81)90059-4
5.
RatnerBDHoffmanAS.Biomaterials science: an introduction to materials in medicine. 3rd ed. Academic Press, 2012. doi:10.1016/B978-0-08-087780-8.00025-5.
6.
YunYHLeeBKParkK.Controlled drug delivery: historical perspective for the next generation. J Control Release. 2015;219:2–7. doi: 10.1016/j.jconrel.2015.10.005
7.
UhrichKECannizzaroSMLangerRSPolymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181–3198. doi: 10.1021/cr940351u
8.
RothsteinSNFederspielJLittleSR.A simple model framework for the prediction of controlled release from bulk eroding polymer matrices. J Mater Chem. 2008;18:1873–1880. doi: 10.1039/b718277e
PurcellBPLobbDCharatiMBInjectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014;13(6):653–661. doi: 10.1038/nmat3922
11.
TimkoBPDvirTKohaneDS.Remotely triggerable drug delivery systems. Adv Mater. 2010;22(44):4925–4943. doi: 10.1002/adma.201002072
12.
FominaNSankaranarayananJAlmutairiA.Photochemical mechanisms of light-triggered release from nanocarriers. Adv Drug Deliv Rev. 2012;64(11):1005–1020. doi: 10.1016/j.addr.2012.02.006
13.
PankhurstQAThanhNKTJonesSKProgress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2009;42:224001–. doi: 10.1088/0022-3727/42/22/224001
14.
HsiehDSTLangerRFolkmanJ.Magnetic modulation of release of macromolecules from polymers. Med Sci. 1981;78(3):1863–1867.
15.
EdelmanERKostJBobeckHRegulation of drug release from polymer matrices by oscillating magnetic fields. J Biomed Mater Res. 1985;19(1):67–83. doi: 10.1002/jbm.820190107
16.
KostJNoeckerRKunicaEMagnetically controlled release systems – effect of polymer composition. J Biomed Mater Res. 1985;19(8):935–940. doi: 10.1002/jbm.820190805
SaslawskiOWeingartenCBenoitJ-PMagnetically responsive microspheres for the pulsed delivery of insulin. Life Sci. 1988;42:1521–1528. doi: 10.1016/0024-3205(88)90009-4
19.
BabincováM.Microwave induced leakage of magnetoliposomes. possible clinical implications. Bioelectrochem Bioenerg. 1993;32(2):187–189. doi: 10.1016/0302-4598(93)80037-U
20.
ViroonchatapanEUenoMSatoHPreparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: an on-line flow system for quantifying magnetic responsiveness. Pharm Res. 1995;12(8):1176–1183. doi: 10.1023/A:1016216011016
21.
TaiL-ATsaiP-JWangY-CThermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology. 2009;20(135101):9.
22.
NappiniSBoniniMRidiFStructure and permeability of magnetoliposomes loaded with hydrophobic magnetic nanoparticles in the presence of a low frequency magnetic field. Soft Matter. 2011;7(10):4801. doi: 10.1039/c0sm01264e
23.
NappiniSBombelliFBBoniniMMagnetoliposomes for controlled drug release in the presence of low-frequency magnetic field. Soft Matter. 2010;6(1):154–162. doi: 10.1039/B915651H
24.
NappiniSBoniniMBombelliFBControlled drug release under a low frequency magnetic field: effect of the citrate coating on magnetoliposomes stability. Soft Matter. 2011;7(3):1025–1037. doi: 10.1039/C0SM00789G
25.
TangYMcGoronAJ.Increasing the rate of heating: a potential therapeutic approach for achieving synergistic tumour killing in combined hyperthermia and chemotherapy. Int J Hyperth. 2013;29(2):145–155. doi: 10.3109/02656736.2012.760757
26.
KulshresthaPGogoiMBahadurDIn vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. Colloids Surface B2012;96:1–7. doi: 10.1016/j.colsurfb.2012.02.029
BabincováMCicmanecPAltanerováVAC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry. 2002;55(1–2):17–19. doi: 10.1016/S1567-5394(01)00171-2
29.
HardiansyahAHuangL-YYangM-CMagnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment. Nanoscale Res Lett. 2014;9(1):497. doi: 10.1186/1556-276X-9-497
30.
ThomasCRFerrisDPLeeJ-HNoninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc. 2010;132(31):10623–10625. doi: 10.1021/ja1022267
31.
LuoSWangLDingWClinical trials of magnetic induction hyperthermia for treatment of tumours. OA Cancer. 2014;2(1):2.
32.
EstelrichJEscribanoEQueraltJIron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci. 2015;16:8070–8101. doi: 10.3390/ijms16048070
33.
BoniniMBertiDBaglioniP.Nanostructures for magnetically triggered release of drugs and biomolecules. Curr Opin Colloid Interface Sci. 2013;18(5):459–467. doi: 10.1016/j.cocis.2013.07.007
34.
PankhurstQAConnollyJJonesSKApplications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 2003;36:R167–R181.
35.
WildeboerRRSouthernPPankhurstQA.On the reliable measurement of specific absorption rates and intrinsic loss parameters in magnetic hyperthermia materials. J Phys D Appl Phys. 2014;47(495003):14.
36.
ChristiansenMGSenkoAWChenRMagnetically multiplexed heating of single domain nanoparticles. Appl Phys Lett. 2014;104(21):213103. doi: 10.1063/1.4879842
37.
MonnierCABurnandDRothen-RutishauserBMagnetoliposomes: opportunities and challenges. Eur J Nanomed. 2014;6(4):201–215. doi: 10.1515/ejnm-2014-0042
38.
KozissnikBBohorquezACDobsonJMagnetic fluid hyperthermia: advances, challenges, and opportunity. Int J Hyperthermia2013;29(8):706–714. doi: 10.3109/02656736.2013.837200
39.
FelfoulOBeckerATFagogenisGSimultaneous steering and imaging of magnetic particles using MRI toward delivery of therapeutics. Sci Rep. 2016;6:14. doi: 10.1038/srep33567
40.
SangerFTuppyH.The amino-acid sequence in the phenylalanyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem J.1951;49:463–481. doi: 10.1042/bj0490463
LeaderBBacaQJGolanDE.Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–39. doi: 10.1038/nrd2399
43.
WuFJinT.Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech. 2008;9(4):1218–1229. doi: 10.1208/s12249-008-9148-3
44.
RothsteinSNHuberKDSluis-CremerNIn vitro characterization of a sustained-release formulation for enfuvirtide. Antimicrob Agents Chemother. 2014;58(3):1797–1799. doi: 10.1128/AAC.02440-13
45.
VaishyaRKhuranaVPatelSLong-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12(3):415–440. doi: 10.1517/17425247.2015.961420
46.
DavisBK.Diffusion in polymer gel implants. Proc Natl Acad Sci USA. 1974;71(8):3120–3123. doi: 10.1073/pnas.71.8.3120
47.
LangerRFolkmanJ.Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263(5580):797–800. doi: 10.1038/263797a0
48.
Health C for D and R. Recently-Approved Devices – InFUSETM Bone Graft/LT-CAGETM Lumbar Tapered Fusion Device – P000058.
49.
FrokjaerSOtzenDE.Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298–306. doi: 10.1038/nrd1695
50.
Health C for D and R. Recently-Approved Devices – OP-1 Putty – H020008.
AgarwalPRupenthalID.Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today. 2013;18(7):337–349. doi: 10.1016/j.drudis.2013.01.013
53.
WatsonJDCrickFHC.Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature. 1953;171:737–738. doi: 10.1038/171737a0
54.
WilsonRF.The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am J Law Med. 2010;36(2–3):295–325. doi: 10.1177/009885881003600202
55.
SchererFAntonMSchillingerUMagnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002;9:102–109. doi: 10.1038/sj.gt.3301624
56.
VernonMDeanDDobsonJ.DNA targeting sequence improves magnetic nanoparticle-based plasmid DNA transfection efficiency in model neurons. Int J Mol Sci. 2015;16(8):19369–19386. doi: 10.3390/ijms160819369
57.
McBainSCGriesenbachUXenariouSMagnetic nanoparticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays. Nanotechnology. 2008;19(40):405102. doi: 10.1088/0957-4484/19/40/405102
58.
HawkinsT.DNA purification and isolation using magnetic particles. 1994.
59.
JohnsonI.Human insulin from recombinant DNA technology. Science. 1983;219(4585):632–637. doi: 10.1126/science.6337396
60.
HultmanTStahlSHornesEDirect solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 1989;17(13):4937–4946. doi: 10.1093/nar/17.13.4937
61.
SefahKShangguanDXiongXDevelopment of DNA aptamers using cell-SELEX. Nat Protoc. 2010;5(6):1169–1185. doi: 10.1038/nprot.2010.66
62.
KulbachinskiyAV.Methods for selection of aptamers to protein targets. Biochemistry. 2007;72(13):1505–1518.
63.
KeefeADPaiSEllingtonA.Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537–550. doi: 10.1038/nrd3141
64.
JayasenaSD.Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999;45(9):1628–1650.
65.
MorishitaMPeppasNA.Is the oral route possible for peptide and protein drug delivery?Drug Discov Today. 2006;11(19):905–910. doi: 10.1016/j.drudis.2006.08.005
66.
CohnEJStrongLEHughesWL. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68(2):459–475. doi: 10.1021/ja01207a034
67.
ScopesRK.Overview of protein purification and characterization. Curr Protoc Protein Sci., Hoboken, NJ, USA: John Wiley & Sons, Inc., 1995; Chapter 1, 68:1.1.1–1.1.6. doi: 10.1002/0471140864.ps0101s00
68.
LangerRSRhineWDHsiehDSTPolymers for the sustained release of macromolecules: applications and control of release kinetics. Control Release Bioact Mater. 1980:83–98. doi: 10.1016/B978-0-12-074450-3.50009-7
69.
GombotzWRWeeSF.Protein release from alginate matrices. Adv Drug Deliv Rev. 2012;64:194–205. doi: 10.1016/j.addr.2012.09.007
70.
ZhaoXKimJCezarCAActive scaffolds for on-demand drug and cell delivery. Proc Natl Acad Sci USA. 2011;108(1):67–72. doi: 10.1073/pnas.1007862108
71.
CezarCAKennedySMMehtaMBiphasic ferrogels for triggered drug and cell delivery. Adv Healthcare Mater. 2014;3(11):1869–1876. doi: 10.1002/adhm.201400095
72.
KimHParkHLeeJWMagnetic field-responsive release of transforming growth factor beta 1 from heparin-modified alginate ferrogels. Carbohydr Polym. 2016;151:467–473. doi: 10.1016/j.carbpol.2016.05.090
73.
KaurLSinghJLiuQ.Starch – a potential biomaterial for biomedical applications. In: MozafariM. Reza, editor. Nanomater nanosyst biomed appl.Springer Netherlands; 2007. p. 83–98.
74.
GuilhermeMROliveiraRSMauricioMRAlbumin release from a brain-resembling superabsorbent magnetic hydrogel based on starch. Soft Matter. 2012;8(24):6629. doi: 10.1039/c2sm25638j
75.
PeppasNA.Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110–111.
76.
FinotelliPVDa SilvaDSola-PennaMMicrocapsules of alginate/chitosan containing magnetic nanoparticles for controlled release of insulin. Colloids Surface B. 2010;81(1):206–211. doi: 10.1016/j.colsurfb.2010.07.008
77.
CroisierFJérômeC.Chitosan-based biomaterials for tissue engineering. Eur Polym J. 2013;49(4):780–792. doi: 10.1016/j.eurpolymj.2012.12.009
78.
ChenJ-PLiuC-HHsuH-LMagnetically controlled release of recombinant tissue plasminogen activator from chitosan nanocomposites for targeted thrombolysis. J Mater Chem B. 2016;4(15):2578–2590. doi: 10.1039/C5TB02579F
79.
HonarmandDGhoreishiSMHabibiNControlled release of protein from magnetite-chitosan nanoparticles exposed to an alternating magnetic field. J Appl Polym Sci. 2016;133(17):43335–43335. doi: 10.1002/app.43335
80.
ZhengCDingYLiuXHighly magneto-responsive multilayer microcapsules for controlled release of insulin. Int J Pharm. 2014;475(1):17–24. doi: 10.1016/j.ijpharm.2014.08.042
MonsalveABohorquezACRinaldiCRemotely triggered activation of TGF-β with magnetic nanoparticles. IEEE Magn Lett. 2015;6:1–4. doi: 10.1109/LMAG.2015.2477271
83.
BoothAPintreICLinYRelease of proteins and enzymes from vesicular compartments by alternating magnetic fields. Phys Chem Chem Phys. 2015;17(17):15579–15588. doi: 10.1039/C4CP05872K
84.
LimJClementsMDobsonJ. Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis. PLoS One. 2012;7(12):1–7.
85.
MykhaylykOSanchez-AntequeraYVlaskouDMagnetic nanoparticle and magnetic field assisted siRNA delivery in vitro. RNA Interf. 2014;1218:53–106.
86.
DerfusAMVon MaltzahnGHarrisTJRemotely triggered release from magnetic nanoparticles. Adv Mater. 2007;19:3932–3936. doi: 10.1002/adma.200700091
87.
DhaneshwarSKandpalMGairolaNDextran: a promising macromolecular drug carrier. Indian J Pharm Sci. 2006;68(6):705–714. doi: 10.4103/0250-474X.31000
88.
YangYXieXXuXThermal and magnetic dual-responsive liposomes with a cell-penetrating peptide–siRNA conjugate for enhanced and targeted cancer therapy. Colloids Surface B. 2016;146:607–615. doi: 10.1016/j.colsurfb.2016.07.002
89.
DominskaMDykxhoornDM.Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183–1189. doi: 10.1242/jcs.066399
90.
LiuMWangZZongSRemote-controlled DNA release from Fe3O4@Au nanoparticles using an alternating electromagnetic field. J Biomed Nanotechnol. 2015;11:979–987. doi: 10.1166/jbn.2015.2013
91.
ParkJAnKHwangYUltra-large-scale syntheses of monodisperse nanocrystals. Nat Mater. 2004;3(12):891–895. doi: 10.1038/nmat1251
92.
BabincovaMNovotnyJRoseneckerJRemote radio-control of siRNA release from magnetite–hydrogel composite. Optoelectron Adv Mater Commun. 2007;1(11):644–647.
93.
YangT-H.Recent applications of polyacrylamide as biomaterials. Recent Patents Mater Sci. 2008;1(1):29–40. doi: 10.2174/1874464810801010029
94.
HofmannMWollertKCMeyerGPMonitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111:2198–2202. doi: 10.1161/01.CIR.0000163546.27639.AA
95.
SkukDCaronNJGouletMResetting the problem of cell death following muscle-derived cell transplantation: detection, dynamics and mechanisms. J Neuropathol Exp Neurol. 2003;62(9):951–967. doi: 10.1093/jnen/62.9.951
